Annovis Bio (Annovis Bio) Debt-to-Equity : 0.00 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Annovis Bio Debt-to-Equity?

Annovis Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Annovis Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Annovis Bio's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-7.75 Mil. Annovis Bio's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Annovis Bio's Debt-to-Equity or its related term are showing as below:

During the past 7 years, the highest Debt-to-Equity Ratio of Annovis Bio was -0.06. The lowest was -0.06. And the median was -0.06.

ANVS's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Annovis Bio Debt-to-Equity Historical Data

The historical data trend for Annovis Bio's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annovis Bio Debt-to-Equity Chart

Annovis Bio Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.06

Annovis Bio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Annovis Bio's Debt-to-Equity

For the Biotechnology subindustry, Annovis Bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annovis Bio's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annovis Bio's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Annovis Bio's Debt-to-Equity falls into.

Annovis Bio Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Annovis Bio's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	-7.751
	=	0.00

Annovis Bio's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	-7.751
	=	0.00

Annovis Bio (NYSE:ANVS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Annovis Bio Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Annovis Bio's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Annovis Bio (Annovis Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annovis Bio Inc (NYSE:ANVS) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

07X:Germany

Address

1055 Westlakes Drive, Suite 300, Berwyn, PA, USA, 19312

Website

https://www.annovisbio.com

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.

Executives

Henry Iii Hagopian	officer: Chief Financial Officer	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Mark K. White	director	227 7TH AVENUE NE, ST. PETERSBURG FL 33701
Claudine Bruck	director	4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017-3552
Maria-luisa Maccecchini	director, officer: President and CEO	1223 FOXGLOVE LANE, WEST CHESTER PA 19380
Reid Mccarthy	director	1055 WESTLAKES DRIVE, SUITE 300, BERWYN PA 19312
Jeffrey Brian Mcgroarty	officer: Chief Financial Officer	360 HILLTOP RD, PAOLI PA 19301
Whelan, Jr. Robert M.	director	ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Michael B Hoffman	director	1 GREENWICH OFFICE PARK, GREENWICH CT 06831